Are Peptides Legal? Australia Schedule 4, US FDA, UAE Rules (2026)

The Key Legal Distinction: Intended Use

The legality of peptides is not determined by the compound itself. In virtually every major jurisdiction, what matters is how the peptide is sold, labelled, and used. The same molecule can be legal in one context and illegal in another.

The “research use only” label is not a legal loophole. Regulators in the US, UK, and Australia have pursued enforcement where products were technically labelled for research but clearly intended for human use—evidenced by therapeutic marketing claims, inclusion of syringes/diluent, dosing instructions for self-injection, or user reviews indicating personal administration.

United States — FDA Regulatory Status

The FDA Category System

The FDA classifies bulk drug substances used by compounding pharmacies into two categories:

• Category 1: Substances with sufficient safety data—licensed pharmacies may compound them under a physician’s prescription.
• Category 2: Substances presenting “significant safety risks”—cannot be used in compounding unless FDA authorises through formal rulemaking.

This classification only applies to compounding pharmacies. It does not affect research-use peptides sold for laboratory purposes.

The 2023 Category 2 Reclassification

In late 2023, the FDA moved 19 peptides from Category 1 to Category 2, taking them out of the interim compounding pathway for licensed pharmacies while FDA evaluated safety concerns.^[1] Key examples included:

• BPC-157, TB-500 fragment, Thymosin Alpha-1
• CJC-1295, Ipamorelin, AOD-9604, Selank, Semax
• Injectable GHK-Cu, KPV, MOTS-C, Epitalon, Melanotan II, Dihexa acetate, PEG-MGF, Kisspeptin-10, LL-37, and MK-677

In September 2024, the nominations for five peptides were withdrawn: AOD-9604, CJC-1295, Ipamorelin Acetate, Thymosin Alpha-1, and Selank Acetate. FDA’s Category 2 page now lists them as “nominated but withdrawn”.^[1]

April 2026: 12 Category 2 Nominations Withdrawn

The next change came in April 2026, when 12 peptides left Category 2 of the 503A Do-Not-Compound list because their nominations were withdrawn. FDA’s Category 2 page, updated April 22, 2026, now lists them under “Bulk drug substances nominated but withdrawn”.^[1] They are BPC-157, LL-37, DiHexa, DSIP, Epitalon, injectable GHK-Cu, KPV, PEG-MGF, Melanotan II, MOTS-c, Semax, and TB-500.

The change is narrower than many social posts made it sound. It does not approve these peptides as finished drugs, and it does not make open-ended human marketing legal. Nor did it make them compoundable: they were not placed in Category 1 of FDA’s 503A category list (updated May 14, 2026) or on the 503A Bulks List.^[2] On April 15, 2026, Reuters reported that FDA would convene an expert panel to review wider access to some of these peptides,^[15] and a Federal Register notice on April 16, 2026 then scheduled the July 23–24, 2026 PCAC meeting to consider seven of them for affirmative 503A Bulks List inclusion.^[16]

July 2026 PCAC Review

FDA also announced a July 23–24, 2026 Pharmacy Compounding Advisory Committee (PCAC) meeting to review seven peptides for possible inclusion on the 503A bulks list.^[15] The two-day agenda separates the candidates by clinical context. Day 1: BPC-157 (ulcerative colitis), TB-500 (wound healing), MOTS-c (obesity / osteoporosis), KPV (wound / inflammation). Day 2: Semax (cerebral ischemia / migraine / trigeminal neuralgia), Epitalon (insomnia), DSIP / Emideltide (opioid withdrawal / insomnia / narcolepsy).^[14] That review could shape future compounding access, but it is still separate from FDA approval of finished drugs. The committee met on July 23–24, 2026. It voted to recommend six peptides for the 503A bulks list — BPC-157, TB-500 and KPV (each 8–6, 1 abstention), MOTS-c (7–5, 2 abstentions), Semax (8–5, 1 abstention) and Epitalon (7–4, 1 abstention) — and voted against DSIP / Emideltide (6–7, 1 abstention). Its votes are non-binding, and no final FDA action had been published as of October 7, 2026. For the full breakdown of the schedule, indications, and what each outcome would mean, read the July 2026 PCAC peptide review explainer.

Semaglutide Compounding Crackdown

On February 21, 2025, the FDA resolved the semaglutide shortage, triggering compounding deadlines: 503A pharmacies had until April 22, 2025, and 503B outsourcing facilities until May 22, 2025, to stop compounding semaglutide. The Outsourcing Facilities Association filed a lawsuit challenging this determination. For background on approved GLP-1 formulations, see our Rybelsus oral semaglutide guide.

Are Peptides Controlled Substances in the US?

No. Most peptides—including BPC-157, GHK-Cu, and retatrutide—are not DEA-scheduled controlled substances under the Controlled Substances Act. Possession is not a criminal offence under federal drug scheduling law. However, selling them for human consumption constitutes distributing adulterated and misbranded drugs under the Federal Food, Drug, and Cosmetic Act.

Enforcement Cases

The FDA has taken enforcement action against companies selling peptides marketed for human use. Tailor Made Compounding LLC (Kentucky) pleaded guilty to distributing unapproved new drugs including BPC-157, CJC-1295, Ipamorelin, and Selank, resulting in $1.79M forfeiture.^[4] In early 2025, states including Alabama took enforcement action against wellness clinics marketing research-grade peptides as medical treatments.

United Arab Emirates — MoHAP & Research Use

Research peptides for in-vitro laboratory use are available in the UAE. Multiple peptide suppliers operate openly from Dubai, selling compounds labelled “for research use only.”

• Regulatory bodies: MoHAP (Ministry of Health and Prevention) and the Emirates Drug Establishment (EDE) oversee pharmaceutical regulation.
• Controlled substances: Federal Decree Law No. 30 of 2021 governs narcotics and psychotropic substances.^[5] Research peptides are not on the UAE controlled substances list.
• Research market: The UAE has an active peptide research market. Compounds labelled for in-vitro research are available from multiple Dubai-based suppliers.
• Human-use restriction: Any product marketed for human therapeutic use without MoHAP/EDE registration is considered an unregistered pharmaceutical product.

All Remy Research products are labelled “For Research Use Only” and are not intended for human or veterinary administration. For more on the UAE research landscape, see our research peptides UAE guide, our Dubai-specific legality brief, and GLP-1 medications in the UAE.

United Kingdom — MHRA Regulatory Position

• Most research peptides (BPC-157, GHK-Cu, TB-500) remain unscheduled under the Misuse of Drugs Act 1971.
• Peptides are legal to buy and sell when supplied for research and development purposes to qualified buyers (laboratories, universities, research facilities).
• The MHRA prohibits peptides being marketed or sold for human consumption or therapeutic use unless licensed as medicines.
• The MHRA has taken enforcement actions where “research use” labels were contradicted by marketing materials, user reviews, or product packaging indicating personal use.

Australia — TGA & Schedule 4 Classification

Australia has the strictest peptide regulations of any major market.

• BPC-157: Schedule 4 (prescription-only medicine) under the Poisons Standard.^[8] Illegal to possess without a valid prescription. Not approved by TGA for any human indication.
• Semaglutide: Under TGA amendments to the Therapeutic Goods Regulations 1990, pharmacists can no longer compound and supply GLP-1 receptor agonist products, including semaglutide, compounded on or after October 1, 2024.^[7]
• Tirzepatide (Mounjaro): TGA-registered for type 2 diabetes (December 2022) and chronic weight management (September 2024).
• WADA status: BPC-157 is prohibited under the WADA Prohibited List (category S0: Unapproved Substances). Sport Integrity Australia actively enforces this.
• Penalties: Penalties for unauthorised possession or sale of Schedule 4 medicines are set by each state and territory and vary.

Canada — Health Canada Framework

• Peptides regulated under the Food and Drugs Act and Food and Drug Regulations.
• Peptides intended solely for research purposes are permitted for purchase and use in research labs, provided they are not marketed for human consumption.
• A substance is treated as a drug if sold or represented for treating disease or modifying body functions in humans.
• Health Canada has issued safety alerts for unauthorised injectable peptide products sold online, flagging them as posing serious health risks.

European Union — EMA Framework

• The European Medicines Agency classifies peptides as medicinal products requiring centralised approval for human use.
• Peptides sold as research chemicals are legal when properly labelled and supplied to qualified buyers.
• They cannot be marketed as supplements, cosmetics, or medical treatments without EMA approval.
• Customs agencies in EU member states have seized shipments of unapproved peptides. Regulations vary by member state.
• In December 2025, the EMA published updated guidelines on synthetic peptide manufacture (effective June 2026), though these apply to pharmaceutical manufacturing, not research chemical suppliers.

2026 Peptide Legality — Country Comparison

On phone, swipe sideways to compare all five columns.

Is Retatrutide Legal?

Retatrutide (LY-3437943) is not approved anywhere as of October 7, 2026. It is in Phase 3 under Eli Lilly’s TRIUMPH program. TRIUMPH-1 was published in NEJM on September 29, 2026. TRIUMPH-2 (type 2 diabetes) and TRIUMPH-3 (severe obesity with established cardiovascular disease) reported positive topline results on July 23, 2026, and Lilly plans to submit a BLA to the FDA in Q1 2027.^[17] It cannot be legally prescribed, dispensed by a pharmacy, or sold for human consumption in any jurisdiction.

Research-grade retatrutide is available for in-vitro laboratory research from suppliers like Remy Research. All materials are labelled “For Research Use Only” and include independently verified Certificates of Analysis. For the latest on retatrutide’s regulatory path, see our retatrutide approval status tracker.

How to Stay Compliant When Purchasing Research Peptides

• Verify labelling: All research peptides should be clearly marked “For Research Use Only” or “Not for Human or Veterinary Use.”
• Check COA source: A legitimate Certificate of Analysis from an independent third-party lab (e.g., Janoshik Analytical) confirms the product is manufactured and sold as a research compound — our guide on how to verify a Janoshik COA walks through the check.
• Know your jurisdiction: Regulations vary significantly. Australia restricts BPC-157 as Schedule 4; the US does not schedule it at all. Check local laws before ordering.
• Understand the grey market: Our grey market peptides explainer covers how research-use supply differs from compounded and prescription supply.
• Avoid therapeutic claims: Any supplier making claims about treating, curing, or preventing disease is operating outside legal boundaries in every major jurisdiction.
• Document research purpose: Maintain records of your research protocol and intended use, especially when importing peptides across borders.